What Is the Life Expectancy of Someone With Angina?

Most people diagnosed with stable angina live for many years, and many survive into old age. The Whitehall Study, which tracked men from age 70 onward, found that a diagnosis of angina alone reduced median life expectancy by about two years compared to men without heart disease.¹ That is a real but modest reduction, and it varies enormously depending on the type of angina, how well the heart muscle is functioning, and whether other conditions like diabetes or kidney disease are present. The range of outcomes spans from nearly normal life expectancy for some women with stable angina to sharply shortened survival for people with severe blockages and multiple comorbidities.

The Baseline Numbers for Stable Angina

Stable angina, the kind that comes on predictably with exertion and goes away with rest, carries an average annual death rate of about 4% in broad, unselected patient populations.² That figure comes from older data, and modern treatments have likely improved it, but it remains a reasonable ballpark. To put it in context, a 4% annual mortality means that roughly four out of every hundred people with stable angina will die in a given year, compared to perhaps one or two out of a hundred in the general population of the same age.

A Swedish follow-up study that tracked patients with stable angina for over nine years paints a more nuanced picture. Over the full observation period, about 19% of men died compared to 6% of women. Men had noticeably higher death rates than a matched reference population during the first three years after diagnosis, but that gap appeared to close after year three. Women with stable angina, on the other hand, had mortality that was similar to women in the general population throughout the entire nine-year period.³ That is a striking finding: for women, a stable angina diagnosis did not seem to shorten life at all over nearly a decade of follow-up.

Why the Type of Angina Changes Everything

Not all angina is created equal, and lumping every type together would badly mislead anyone trying to understand their prognosis. The major categories differ substantially in what they mean for long-term survival.

Stable Versus Unstable Angina

Unstable angina, which occurs unpredictably and at rest, signals a more immediate threat. Medically treated patients with unstable angina face a hospital mortality of roughly 3% to 5% and a first-year death rate of 7% to 8%, roughly double the annual risk of stable angina.² A large comparison of patients who underwent coronary stenting found six-year mortality was about 12% for those who had stable angina, 16% for those with unstable angina, and 19% for those who had presented with a full heart attack. The early months after an acute event drove most of that difference; from six months onward, the death rate actually accrued faster in the unstable angina group than in the heart attack group, possibly because unstable angina patients tended to have more widespread underlying disease and more comorbidities.⁴

Vasospastic (Variant) Angina

Vasospastic angina, sometimes called Prinzmetal angina, is caused by temporary spasm of a coronary artery rather than a fixed blockage. The long-term outlook is generally favorable. One study of 245 patients followed for an average of nearly seven years found five-year survival of 97% and ten-year survival of 93%.⁵ A second study, using a different patient cohort, reported five-year survival of 89%, with worse outcomes among people who also had blockages in multiple coronary arteries. In that group, five-year survival dropped to 77%.⁶ Calcium channel blockers, which relax the artery walls and prevent spasm, emerged as one of the strongest predictors of better survival in both studies.

The exception is the small subset of vasospastic angina patients who have survived a cardiac arrest. In a Japanese registry study, those patients had markedly worse five-year outcomes, with only 72% free of major cardiac events compared to 92% of vasospastic angina patients without a cardiac arrest history.⁷

Microvascular Angina

Microvascular angina affects the tiny vessels within the heart muscle rather than the large coronary arteries, and it has historically been dismissed as benign. That view has been revised. A study comparing patients with microvascular disease to an age- and sex-matched general population found that survival was worse than expected, though still better than in people with significant large-vessel coronary artery disease.⁸ Another study found that among patients with chest pain and normal-looking coronary arteries, those with impaired blood flow through the small vessels had a death rate of 20% over follow-up compared to 7% in those with normal flow.⁹

More recent research using comprehensive testing of coronary function found that patients with dysfunction in their small vessels had roughly double the rate of adverse events compared to those with normal test results, though this was driven mainly by emergency visits for chest pain rather than by deaths or heart attacks, which remained low in both groups.¹⁰ Microvascular angina shortens life somewhat and causes a great deal of day-to-day misery, but the mortality risk falls well below that of obstructive coronary disease.

The Factors That Shift Prognosis Most

Knowing the type of angina gives you a starting point, but several other variables move the needle far more dramatically. Doctors use clinical scoring systems that combine multiple factors to estimate the chance of death or heart attack within a given period, and the strongest predictors tend to be how well the heart pumps, how many arteries are affected, and what other diseases are present.¹¹

Left ventricular function, meaning how effectively the heart’s main pumping chamber contracts, is among the most powerful predictors. The survival benefit of coronary bypass surgery, for instance, depends heavily on how much heart muscle is at risk, the severity of the blockages, and how well the ventricle is working.¹² When the pumping function is already impaired, outcomes are considerably worse regardless of treatment approach.

Diabetes

Diabetes stands out as one of the most damaging comorbidities for anyone with angina. In the OASIS registry, diabetes independently raised the risk of death by about 57%, and the effect was even larger in women, where it nearly doubled mortality risk.¹³ Among patients who presented with unstable angina, one-year mortality was more than twice as high in those with diabetes compared to those without, at roughly 7% versus 3%.¹⁴ Diabetes accelerates the underlying artery disease, impairs the body’s ability to develop collateral blood flow, and makes nearly every complication more likely.

Kidney Disease

Chronic kidney disease may be even more ominous. In one study, three-year survival for angina patients with chronic kidney disease was only 65%, compared to 97% in those without kidney problems. Even the in-hospital death rate was dramatically higher: about 9% versus less than 1%.¹⁵ Kidney disease amplifies cardiovascular risk through several routes, including chronic inflammation, accelerated calcium buildup in artery walls, and fluid overload that strains the heart.

How Sex and Age Influence Outcomes

The sex difference in angina survival deserves a closer look because it is more complicated than “women do better.” In the Swedish APSIS study, women with stable angina had survival rates essentially identical to the general female population. Men had clearly elevated risk.³ But a large population-based study found a wrinkle: younger women who had angina confirmed by exercise testing actually had higher relative mortality compared to the general population than men of the same age did. Women aged 55 to 64 with confirmed angina had roughly a fivefold increase in coronary death risk relative to the general population, versus about a twofold increase for men that age.¹⁶ The likely explanation is that when a younger woman develops angina serious enough to trigger a positive stress test, it signals more aggressive underlying disease than it might in a man of the same age, where coronary disease is statistically more common.

Age itself is a major predictor. One large study of patients with refractory angina (symptoms that persist despite all available treatments) found baseline age to be one of the strongest predictors of death, alongside diabetes, kidney disease, heart failure, and the severity of angina symptoms.¹⁷ This is not surprising, but it means that a 50-year-old and an 80-year-old with identical angina symptoms face very different absolute risks.

Depression as a Hidden Risk Multiplier

One of the most underappreciated threats to survival in people with angina is depression. This is not a vague “stress is bad for you” observation; the numbers are large and consistent. In patients hospitalized for unstable angina, those who were depressed had nearly five times the odds of dying or having a heart attack compared to nondepressed patients, and that gap widened to nearly seven times after adjusting for other risk factors like the number of blocked arteries and the heart’s pumping strength.¹⁸

This is not limited to the acute hospital setting. A population-based study found that patients who developed depression after being diagnosed with stable angina had an 83% higher risk of death than those who did not become depressed.¹⁹ A separate study of unstable angina patients confirmed the pattern, finding that even moderate depressive symptoms roughly doubled the risk of death over about three and a half years of follow-up.²⁰ The mechanisms probably involve both biology (depression raises inflammation, disrupts heart rate variability, and activates stress hormones) and behavior (depressed patients exercise less, eat worse, and are less likely to take their medications). Either way, treating depression is not just a quality-of-life concern; it likely affects survival.

What Treatments Actually Extend Life

The good news is that several interventions have clear evidence of improving survival in people with angina, and the gains are large enough to meaningfully shift life expectancy.

Medications

The cornerstone drugs for coronary artery disease include antiplatelet agents like aspirin, statins, ACE inhibitors, and beta-blockers. A study examining ten-year mortality after coronary procedures found that patients who were on both an antiplatelet drug and a statin had roughly half the death rate of those who were not.²¹ Sticking with these medications matters enormously. An analysis of patients with coronary artery disease found that nonadherence to statins was associated with an 85% higher risk of dying, and nonadherence to ACE inhibitors raised the risk by 74%. Even beta-blocker nonadherence increased death risk by 50%.²² These are among the largest effect sizes in cardiology, and they come from simply continuing to take pills already prescribed.

Stents Versus Medications for Stable Angina

Many people assume that having a stent placed will extend their life, but the evidence for stable angina tells a different story. A meta-analysis of randomized trials comparing initial stent placement plus medical therapy versus medical therapy alone for stable coronary artery disease found no significant reduction in death, heart attack, or unplanned future procedures after a mean follow-up of about four years.²³ Stents do relieve symptoms, and for some patients the improvement in quality of life is substantial. But if the question is strictly about living longer, optimal drug therapy achieves similar results for most people with stable angina.

Cardiac Rehabilitation

Exercise-based cardiac rehabilitation is sometimes overlooked in stable angina, but its survival benefit is substantial. An observational study using Dutch insurance data found a 31% lower risk of death among stable angina patients who participated in cardiac rehabilitation compared to those who did not, regardless of whether they had undergone a procedure. This aligns with the broader finding of about a 32% mortality reduction associated with rehabilitation across different cardiac diagnoses.²⁴ Rehabilitation involves supervised exercise, but also typically addresses diet, medication management, and psychological wellbeing, all of which independently affect outcomes.

Smoking Cessation

Quitting smoking after a coronary procedure was associated with an estimated gain of at least two years of life expectancy in a long-term follow-up study. The 30-year cumulative survival rate was 29% in quitters versus 14% in those who kept smoking, and after accounting for baseline differences, cessation remained independently linked to a 43% lower death rate.²⁵ Two extra years may sound modest, but it is comparable to or greater than the benefit of many medications, and the quality of those years tends to be better too.

Why Risk Scores Exist and When They Help

Doctors increasingly use clinical scoring systems to estimate prognosis for individual patients with angina. The Euro Heart Survey score, for example, incorporates factors like the presence of other illnesses, diabetes, symptom severity, how long symptoms have been present, and heart function to produce a one-year estimate of the chance of death or heart attack.¹¹ Other validated scores use similar clinical features and have been shown to work in community-based populations, not just academic medical centers.²⁶

These scores are useful because they capture what population averages cannot: the interaction among multiple risk factors in a single person. A 60-year-old with stable angina, preserved heart function, no diabetes, and no kidney disease occupies a completely different risk category than a 75-year-old with the same angina symptoms who also has diabetes and impaired kidney function. The first person may have near-normal life expectancy. The second faces a dramatically foreshortened one. Average survival figures for “someone with angina” obscure this spread, which is why your cardiologist may give you a personalized risk estimate rather than a single number.

When Symptoms Persist Despite Everything

A subset of angina patients continue to have disabling chest pain despite maximum medical therapy, lifestyle changes, and procedures. This is called refractory angina, and it presents a distinct challenge. Predictors of death in this group include age, diabetes, kidney disease, how poor the heart’s pumping function has become, and the severity of angina symptoms themselves.¹⁷ Interestingly, a study of unstable angina patients found that while the initial severity classification predicted outcomes during the first year, by seven years the event rates had equalized across all severity classes. The initial classification lost its prognostic power over time, suggesting that what happens during those early months and how aggressively the disease is managed matters more than the initial severity label.²⁷

For people living with refractory angina, the practical implication is that survival is still possible for many years, but the disease exerts its toll through reduced quality of life, repeated hospitalizations, and the cumulative burden of comorbid conditions. Newer therapies like spinal cord stimulation, enhanced external counterpulsation, and investigational drugs offer symptom relief in some patients, though their effects on survival remain less well established than those of the core medical therapies.

1
PubMed. Survival in relation to angina symptoms and diagnosis among men aged 70-90 years: the Whitehall Study
2
PubMed. The prognosis in stable and unstable angina
3
PubMed Central. Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)
4
PubMed. Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris
5
PubMed. Long-term prognosis for patients with variant angina and influential factors
6
PubMed. Long-term prognosis of patients with variant angina
7
PubMed. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest
8
PubMed Central. Reduced survival in patients with “coronary microvascular disease”
9
PubMed Central. Mortality in patients with microvascular disease
10
PubMed. Patients with angina and non-obstructive coronary artery disease undergoing comprehensive invasive coronary function testing: long-term clinical outcomes
11
PubMed Central. Predicting prognosis in stable angina–results from the Euro heart survey of stable angina: prospective observational study
12
Journal of Cardiac Surgery. Triple Vessel Coronary Artery Disease Needs a Consistent Definition for Management Guidelines
13
PubMed. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction
14
JAMA. Diabetes and Mortality Following Acute Coronary Syndromes
15
PubMed. Prognosis for patients with angina pectoris accompanied by chronic renal failure
16
JAMA. Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men
17
PubMed. Long-term survival in patients with refractory angina
18
PubMed. Depression and 1-year prognosis in unstable angina
19
PubMed. Clinical Impact of Subsequent Depression in Patients With a New Diagnosis of Stable Angina: A Population-Based Study
20
PubMed Central. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES])
21
Journal of the American College of Cardiology. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization
22
American Heart Journal. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease
23
JAMA Internal Medicine. Initial Coronary Stent Implantation With Medical Therapy vs Medical Therapy Alone for Stable Coronary Artery Disease: Meta-analysis of Randomized Controlled Trials
24
PubMed Central. Exercise-based cardiac rehabilitation in stable angina pectoris: a narrative review on current evidence and underlying physiological mechanisms
25
The American Journal of Cardiology. Life-Years Gained by Smoking Cessation After Percutaneous Coronary Intervention
26
The American Journal of Medicine. Validation of a Simple Clinical Scoring System to Predict Mortality and Events in Patients Being Evaluated for Coronary Artery Disease
27
Journal of the American College of Cardiology. Unstable Angina: Good Long-Term Outcome After a Complicated Early Course